

REMARKS

Entry of the above amendments prior to examination is respectfully requested.

I. Amendments

A. Amendments to the Specification

Amendments to the specification have been made to reflect the status of the parent application and to correct inadvertent typographical errors. As such, no new matter has been added by these amendments.

B. Amendments to the Claims

Claim 1 has been amended to recite a polypeptide which is immunoreactive with an antibody that is itself immunoreactive with human prostatic acid phosphatase (PAP) comprising an amino acid sequence presented as SEQ ID NO: 2, including conservative amino acid substitutions that do not alter the sequence by more than 10%. Support for this amendment can be found at page 9, lines 13 to page 10, line 13, Example 3, and claims 1 and 3 as originally filed.

Claims 2-22 have been cancelled.

New claims 23-26 have been added. Support for these new claims can be found at page 9, lines 13 to page 10, line 13, Example 3, and claims 10-13, now cancelled.

No new matter has been added by these amendments.

II. Conclusion

In view of the above amendments and remarks, Applicants submit that the claims now pending are in condition for allowance. A Notice of Allowance is, therefore, respectfully requested.

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4402.

Respectfully submitted,



Judy M. Mohr
Registration No. 38,563

Date: 2/4/04

Correspondence Address:
Customer No. 22918